Despite major advances in non-invasive diagnostic methods, including imaging techniques such as ultrasound, MRI or CT scans, currently only the removal of endometriotic lesions via laparoscopy under general anesthesia and their histological analysis enables the diagnosis of endometriosis with certainty. The average delay between disease onset and its effective diagnosis is estimated between 7 to 11 years. This significant delay due to the lack of a non invasive diagnostic test, leads to frequent misdiagnosis and associated unsuitable treatments, as well as to more severe cases as the disease may progress and damage additional organs.
Endodiag believes that the development of a non-invasive and reliable diagnostic test based on disease-specific biomarkers will allow a simpler, earlier and more systematic screening of patients. This would enable physicians to make informed medical decisions to prevent disease progression and potentially safeguard fertility.
EndoDTect® is a blood test based on the analysis of a combination of biomarkers. Changes in their expression levels indicate if a subject has endometriosis or not. Combining high sensitivity and specificity, EndoDTect® has the potential to dramatically reduce diagnosis delays. Endodiag is currently conducting validation studies to confirm the predictive value of EndoDTect® for disease detection.
Endodiag has partnerships with prestigious medical, academic and industrial teams around the world. We believe that such collaborations are key enablers to achieve our vision and change the lives of millions of women. If you have a collaborative project that you would like to discuss with us, please contact us at